⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201980 | 0.70 | — | — | |
| SCHEMBL8658713 | 0.67 | — | — | |
| Furan-2(5H)-One SCHEMBL25302 | 0.64 | — | — | |
| SCHEMBL8121232 | 0.64 | — | — | |
| SCHEMBL9051083 | 0.64 | CA1 (0.46) | — | |
| Furan-2(5H)-One SCHEMBL31686414 | 0.62 | — | — | |
| Furan-2(5H)-One SCHEMBL28520105 | 0.62 | — | — | |
| Furan-2(5H)-One SCHEMBL5619697 | 0.59 | CA1 (0.73) | — | |
| SCHEMBL13415918 | 0.59 | MAOA (0.50) | — | |
| SCHEMBL17670680 | 0.58 | CA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611466-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | President and Fellows of Harvard College (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012074588-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-07 | — | — | WO | claimed |
| US-12042525-B2 | Serum response factor regenerates senescent cells | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-11946939-B2 | Biomarkers and methods for assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240091232-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024050261-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240077499-A1 | METHODS FOR CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS | CRESCENDO BIOSCIENCE, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240024430-A1 | SYNTHETIC PLATELETS | UNIV CASE WESTERN RESERVE (US) | 2024-01-25 | — | — | US | disclosed |
| EP-3682240-B1 | ASSESSING MYOCARDIAL INFARCTION AND SERIOUS INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTS | LABORATORY CORP AMERICA HOLDINGS (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4296678-A2 | ASSESSING MYOCARDIAL INFARCTION AND SERIOUS INFECTION RISK IN RHEUMATOID ARTHRITIS PATIENTS | Laboratory Corporation of America Holdings (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20050074448-A1 | Increasing nitric oxide production; nitric oxide synthase havingTAT protein transduction domain; vascular diseases | THE CURATOR SOF THE UNIVERSITY OF MISSOURI | 2005-04-07 | — | — | US | disclosed |
| US-6846670-B2 | Genetically engineered herpes virus for the treatment of cardiovascular disease | THE UNIVERSITY OF CHICAGO (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2004112763-A2 | INHIBITION OF PROTEIN KINASE C-MU (PKD) AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1434876-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | The REGENTS OF THE UNIVERSITY OF COLORADO, A Body Corporate (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1356071-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | The University of Chicago (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030096782-A1 | Expression profiling in the intact human heart | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2003-05-22 | — | — | US | disclosed |
| WO-2003023066-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020155432-A1 | Genetically engineered herpes virus for the treatment of cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| WO-2002045431-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF CHICAGO (US) | 2002-06-06 | — | — | WO | disclosed |